Literature DB >> 10598918

Pattern of parvovirus B 19 infection during different trimesters of pregnancy in Kuwait.

M Makhseed1, A Pacsa, M A Ahmed, S S Essa.   

Abstract

OBJECTIVE: Aims of this study were to determine the IgG and IgM seropositivity to parvovirus B19 during the three trimesters of pregnancy.
METHODS: Initially, a total of 1,047 pregnant women were included in a prospective study. Blood samples were obtained from 343, 406 and 298 cases in the first, second and third trimesters, respectively. To study the incidence of seroconversion, a second sample of blood was obtained 2-4 weeks later from the first 100 cases, who were IgG and IgM negative in the first trimester.
RESULTS: The seroprevalence of parvovirus B19 IgG and IgM was 53.3% and 2.2%, respectively. The incidence of seroconversion was 16.5%. The rate of fetal loss was 15.4% in patients with acute infection, all of which occurred in the first two trimesters.
CONCLUSIONS: The percentage of IgG positive cases is significantly higher in first and second trimesters compared to the third trimester. The seroconversion rate was 16.5%.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10598918      PMCID: PMC1784763          DOI: 10.1002/(SICI)1098-0997(1999)7:6<287::AID-IDOG7>3.0.CO;2-M

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  22 in total

Review 1.  Human parvovirus B19 infections in pregnancy.

Authors:  T J Török
Journal:  Pediatr Infect Dis J       Date:  1990-10       Impact factor: 2.129

2.  Parvovirus infections and hypoplastic crisis in sickle-cell anaemia.

Authors:  J R Pattison; S E Jones; J Hodgson; L R Davis; J M White; C E Stroud; L Murtaza
Journal:  Lancet       Date:  1981-03-21       Impact factor: 79.321

3.  Human parvovirus B19 infection in pregnancy.

Authors:  T F Schwarz; M Roggendorf; B Hottenträger; F Deinhardt; G Enders; K P Gloning; T Schramm; M Hansmann
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

Review 4.  Parvovirus B19: an expanding spectrum of disease.

Authors:  B Cohen
Journal:  BMJ       Date:  1995-12-09

5.  Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study.

Authors:  J F Rodis; D L Quinn; G W Gary; L J Anderson; S Rosengren; M L Cartter; W A Campbell; A M Vintzileos
Journal:  Am J Obstet Gynecol       Date:  1990-10       Impact factor: 8.661

6.  The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome.

Authors:  E Gratacós; P J Torres; J Vidal; E Antolín; J Costa; M T Jiménez de Anta; V Cararach; P L Alonso; A Fortuny
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

7.  Outbreak of aplastic crises in sickle cell anaemia associated with parvovirus-like agent.

Authors:  G R Serjeant; J M Topley; K Mason; B E Serjeant; J R Pattison; S E Jones; R Mohamed
Journal:  Lancet       Date:  1981-09-19       Impact factor: 79.321

8.  Risk of human parvovirus B19 infections among school and hospital employees during endemic periods.

Authors:  S P Adler; A M Manganello; W C Koch; S H Hempfling; A M Best
Journal:  J Infect Dis       Date:  1993-08       Impact factor: 5.226

9.  Parvovirus-like particles in human sera.

Authors:  Y E Cossart; A M Field; B Cant; D Widdows
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

10.  A prospective study of antibodies against parvovirus B19 in pregnancy.

Authors:  L Skjöldebrand-Sparre; E Fridell; M Nyman; B Wahren
Journal:  Acta Obstet Gynecol Scand       Date:  1996-04       Impact factor: 3.636

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.